150 related articles for article (PubMed ID: 32233152)
1. Subthreshold Micropulse Yellow Laser (577 nm) for Idiopathic Macular Telangiectasia Type 1 Resistant to Intravitreal Injection.
Kang YK; Park HS
Korean J Ophthalmol; 2020 Apr; 34(2):168-169. PubMed ID: 32233152
[No Abstract] [Full Text] [Related]
2. Long-Term Follow-Up of an Atypical Case of Idiopathic Macular Telangiectasia.
Mucciolo DP; Murro V; Giorgio D; Sodi A; Virgili G; Rizzo S
Ophthalmic Surg Lasers Imaging Retina; 2018 Dec; 49(12):e278-e283. PubMed ID: 30566714
[TBL] [Abstract][Full Text] [Related]
3. Fluorescein Angiography Versus Optical Coherence Tomography Angiography in Macular Telangiectasia Type I Treated With Bevacizumab Therapy.
Yannuzzi NA; Gregori NZ; Roisman L; Gupta N; Goldhagen BE; Goldhardt R
Ophthalmic Surg Lasers Imaging Retina; 2017 Mar; 48(3):263-266. PubMed ID: 28297041
[TBL] [Abstract][Full Text] [Related]
4. Macular Telangiectasia Type 1 Managed With Long-Term Aflibercept Therapy.
Kovach JL; Hess H; Rosenfeld PJ
Ophthalmic Surg Lasers Imaging Retina; 2016 Jun; 47(6):593-5. PubMed ID: 27327292
[TBL] [Abstract][Full Text] [Related]
5. Comparison of anatomical and visual outcomes following different anti-vascular endothelial growth factor treatments in subretinal neovascular membrane secondary to type 2 proliferative macular telangiectasia.
Karasu B; Gunay BO
Graefes Arch Clin Exp Ophthalmol; 2020 Jan; 258(1):99-106. PubMed ID: 31768680
[TBL] [Abstract][Full Text] [Related]
6. Macular Hole Formation after Intravitreal Injection of Bevacizumab for Diabetic Macular Edema.
Lee YJ; Kim M
Korean J Ophthalmol; 2019 Apr; 33(2):198-199. PubMed ID: 30977331
[No Abstract] [Full Text] [Related]
7. Response to anti-vascular endothelial growth factor of abnormal retinal vascular net in para foveal telangiectasia group II images on optical coherence tomography-angiography.
Saoji K; Pathengay A; Chhablani J; Panchal B; Doshi S; Saldanha M
Indian J Ophthalmol; 2019 Jan; 67(1):105-108. PubMed ID: 30574903
[TBL] [Abstract][Full Text] [Related]
8. MACULAR CHOROIDAL VOLUME CHANGES AFTER INTRAVITREAL BEVACIZUMAB FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION.
Palkovits S; Seidel G; Pertl L; Malle EM; Hausberger S; Makk J; Singer C; Osterholt J; Herzog SA; Haas A; Weger M
Retina; 2017 Dec; 37(12):2262-2268. PubMed ID: 28129216
[TBL] [Abstract][Full Text] [Related]
9. Role of intravitreal bevacizumab in adult onset Coats' disease.
Goel N; Kumar V; Seth A; Raina UK; Ghosh B
Int Ophthalmol; 2011 Jun; 31(3):183-90. PubMed ID: 21437759
[TBL] [Abstract][Full Text] [Related]
10. EFFICACY OF INTRAVITREAL AFLIBERCEPT IN MACULAR TELANGIECTASIA TYPE 1 IS LINKED TO THE OCULAR ANGIOGENIC PROFILE.
Kowalczuk L; Matet A; Dirani A; Daruich A; Ambresin A; Mantel I; Spaide RF; Turck N; Behar-Cohen F
Retina; 2017 Dec; 37(12):2226-2237. PubMed ID: 28002269
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcomes of switching to aflibercept for treatment-resistant neovascular age-related macular degeneration.
Spooner K; Hong T; Nair R; Chow NCC; Broadhead GK; Wijeyakumar W; Chang AA
Acta Ophthalmol; 2019 Aug; 97(5):e706-e712. PubMed ID: 30740921
[TBL] [Abstract][Full Text] [Related]
12. COMBINATION THERAPY OF INTRAVITREAL RANIBIZUMAB AND SUBTHRESHOLD MICROPULSE PHOTOCOAGULATION FOR MACULAR EDEMA SECONDARY TO BRANCH RETINAL VEIN OCCLUSION: 6-MONTH RESULT.
Terashima H; Hasebe H; Okamoto F; Matsuoka N; Sato Y; Fukuchi T
Retina; 2019 Jul; 39(7):1377-1384. PubMed ID: 29689025
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal injection of a Rho-kinase inhibitor (fasudil) combined with bevacizumab versus bevacizumab monotherapy for diabetic macular oedema: a pilot randomised clinical trial.
Ahmadieh H; Nourinia R; Hafezi-Moghadam A; Sabbaghi H; Nakao S; Zandi S; Yaseri M; Tofighi Z; Akbarian S
Br J Ophthalmol; 2019 Jul; 103(7):922-927. PubMed ID: 30150280
[TBL] [Abstract][Full Text] [Related]
14. Treatment of intravitreal bevacizumab combined with focal laser photocoagulation in the case of macular telangiectasia type 2 with retinal arterial macroaneurysm.
Demir G; Artunay Ö; Sucu ME; Demircan A; Yaşa D; Alagöz C; Öcal MC
Lasers Med Sci; 2019 Mar; 34(2):427-430. PubMed ID: 30027424
[TBL] [Abstract][Full Text] [Related]
15. Treatment of intravitreal bevacizumab combined with focal laser photocoagulation in the case of macular telangiectasia type 2 with retinal arterial macroaneurysm.
Demir G; Artunay Ö; Sucu ME; Demircan A; Yaşa D; Alagöz C; Öcal MC
Lasers Med Sci; 2019 Feb; 34(1):235-238. PubMed ID: 29804166
[TBL] [Abstract][Full Text] [Related]
16. Switching to aflibercept in patients with neovascular age-related macular degeneration not responding to bevacizumab: a pilot study.
van Asten F; Klevering BJ; Hoyng CB
Acta Ophthalmol; 2017 Aug; 95(5):e426-e427. PubMed ID: 27350361
[No Abstract] [Full Text] [Related]
17. EFFICACY AND FREQUENCY OF INTRAVITREAL AFLIBERCEPT VERSUS BEVACIZUMAB FOR MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION.
Lotfy A; Solaiman KAM; Abdelrahman A; Samir A
Retina; 2018 Sep; 38(9):1795-1800. PubMed ID: 28767552
[TBL] [Abstract][Full Text] [Related]
18. Secondary Coats' response to retinal vasculitis managed with bevacizumab.
Chaudhary P; Varshney A; Videkar C
Indian J Ophthalmol; 2018 Sep; 66(9):1355-1357. PubMed ID: 30127171
[TBL] [Abstract][Full Text] [Related]
19. Optical coherence tomography angiography in treated type 2 neovascularization undergoing monthly anti-VEGF treatment.
Parravano M; Querques L; Scarinci F; Giorno P; De Geronimo D; Gattegna R; Varano M; Bandello F; Querques G
Acta Ophthalmol; 2017 Aug; 95(5):e425-e426. PubMed ID: 27496070
[No Abstract] [Full Text] [Related]
20. Two-year functional and anatomical results after converting treatment resistant eyes with exudative age-related macular degeneration to aflibercept in accordance with a treat and extend protocol.
Jørstad ØK; Faber RT; Moe MC
Acta Ophthalmol; 2017 Aug; 95(5):460-463. PubMed ID: 28556485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
